The method leverages preoperative multi-parametric MRI to simultaneously predict key molecular and histopathological features in newly diagnosed glioma patients, including IDH mutation, 1p/19q co-deletion, MGMT promoter methylation, and tumor grade, while also performing automated segmentation of T2w hyperintense regions. This evidence concerns the gene MGMT and central nervous system cancer.